• Obeticholic Acid: FXR Agonist for Liver Fibrosis Research

  2026-06-25

  Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid) is a potent and selective FXR agonist used to modulate bile acid homeostasis and study liver fibrosis. Its robust activity in both in vitro and in vivo models supports its role in hepatic inflammation and portal hypertension research. APExBIO supplies this compound as B4888, enabling advanced translational studies.

• Ciprofloxacin in Research: Advanced Workflows and Real-World

  2026-06-25

  Ciprofloxacin, a benchmark fluoroquinolone antibiotic, is unlocking new experimental strategies in antimicrobial resistance research and beyond. This article dissects the latest workflow innovations, troubleshooting tips, and protocol controls for maximizing reproducible results with APExBIO's high-purity Ciprofloxacin.

• 25HC-Driven AMPK Activation Shapes Immunosuppressive Macroph

  2026-06-24

  Xiao et al. (2024) uncover how 25-hydroxycholesterol (25HC) accumulates in tumor-associated macrophages, activating AMPKα via a lysosomal GPR155-mTORC1 pathway and reprogramming their immunosuppressive function. These findings reveal CH25H as a metabolic checkpoint, reshaping tumor immunity and suggesting new strategies for targeting TAMs in cancer.

• TMEM16F-Mediated Lipid Scrambling Suppresses Ferroptosis in

  2026-06-23

  Yang et al. (2025) identify TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis, revealing how plasma membrane remodeling limits cell death and promotes tumor immune rejection. This mechanistic insight bridges membrane biology and immunotherapy, offering new directions for cancer research.

• BH3 Mimetics Target Chemotherapy-Induced Senescence in Breas

  2026-06-23

  This study demonstrates that BH3 mimetics can selectively eliminate senescent tumor cells that persist after chemotherapy in TP53 wild-type breast cancer. The findings highlight a mechanistic vulnerability in senescent cancer cells and suggest that targeting anti-apoptotic proteins, including MCL1, may significantly improve therapeutic outcomes.

• Staurosporine in Translational Tumor Research: Beyond Apopto

  2026-06-22

  Explore the multifaceted role of Staurosporine as a broad-spectrum serine/threonine protein kinase inhibitor in translational cancer research. This cornerstone article uniquely bridges mechanistic insights with practical assay design, emphasizing anti-angiogenic applications and protocol optimization.

• 3D Electrophysiology in Cardiac Organoids with Shell MEAs

  2026-06-22

  This study introduces programmable shell microelectrode arrays (MEAs) for comprehensive 3D mapping of electrical activity in human cardiac organoids. The platform addresses longstanding limitations of 2D and destructive techniques, enabling high-resolution spatiotemporal analysis and pharmacological screening—advancing cardiac disease modeling and safety research.

• GSK621: Advanced Strategies for AMPK Agonist Use in AML Rese

  2026-06-21

  Explore how GSK621, a potent AMPK agonist, unlocks new capabilities in acute myeloid leukemia research. This article offers an in-depth, evidence-driven analysis of GSK621’s mechanism, protocol nuances, and unique experimental advantages.

• Hydroxyl Radical Degradation Mechanisms of Dimetridazole in

  2026-06-20

  This study delivers a quantum chemical analysis of how hydroxyl radicals degrade Dimetridazole (1,2-dimethyl-5-nitroimidazole) in aqueous environments. It elucidates detailed reaction pathways, kinetic parameters, and the toxicity evolution of intermediates, informing environmental risk and advanced oxidation process design.

• Reliable Necroptosis Inhibition: Lab Scenarios with Necrosta

  2026-06-19

  This article explores real-world laboratory challenges in programmed necrotic cell death assays and demonstrates how Necrostatin 2 (Nec-2, SKU A3652) delivers reproducible, data-driven solutions. Using scenario-driven Q&As, it addresses assay design, data interpretation, and product selection considerations for researchers seeking robust necroptosis inhibition tools.

• AMG 9810 and TRPV1: Beyond Pain—Metabolic Stress & Sensory C

  2026-06-19

  Explore how AMG 9810, a potent TRPV1 antagonist, is reshaping pain mechanism research and sensory neuron signaling studies. This article uniquely bridges TRPV1 inhibition with emerging insights into metabolic stress, offering advanced guidance for translational assay design.

• ZIF8-Based Nanoplatform Enables Synergistic Therapy in TNBC

  2026-06-18

  Li et al. present a folic acid–PEG–modified ZIF8 nanoplatform for targeted delivery of ciprofloxacin, integrating sonodynamic therapy, chemotherapy, and immune activation in triple-negative breast cancer (TNBC). Their multifunctional system offers pH-responsive drug release, ultrasound imaging guidance, and significantly amplified antitumor and immunogenic effects, supporting future theranostic innovation.

• GSK621 (SKU B6020): Reliable AMPK Agonist for Metabolic Rese

  2026-06-18

  This in-depth guide addresses practical laboratory challenges in cell viability, proliferation, and cytotoxicity assays, focusing on how GSK621 (SKU B6020) empowers reproducible AMPK activation. Drawing on peer-reviewed evidence and protocol optimization, it demonstrates why APExBIO’s GSK621 is a robust choice for acute myeloid leukemia and immunometabolic research.

• Applied Workflows with EZ Cap™ Human PTEN mRNA (ψUTP): From

  2026-06-17

  EZ Cap™ Human PTEN mRNA (ψUTP) sets a new benchmark for in vitro transcribed mRNA applications, combining enhanced stability and immune evasion with robust gene expression. Discover how this APExBIO tool streamlines experimental workflows for tumor suppressor restoration and PI3K/Akt pathway inhibition in translational cancer research.

• IPA-3: Selective Non-ATP Pak1 Inhibition for Research

  2026-06-17

  IPA-3 (1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol) is a validated, non-ATP-competitive Pak1 inhibitor. Its high selectivity and distinct mechanism enable precise kinase pathway interrogation and translational studies. IPA-3 from APExBIO is a reference tool in Pak1 autophosphorylation inhibition, cancer biology, and spinal cord injury research.

15556 records 1/1038 page Next 12345 下5页 Last page